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Is The Serum CA125 Level Originating From
Endometrum Influenced by Exogenous Estrogen
Administration?

Abstract: Objectives: To assess the
endometrial contribution of serum CA125
and
its
influence
from
estrogen
administration in menopausal women.
Desing:
A
randomised,
prospective study.

Departments of 1Nuclear Medicine, 2Gynecology
and Obstetrics, Faculty of Medicine,
Gazi University, Ankara-Turkey

controlled,

Materials
and
Methods:
Twenty
menopausal women with intact uterus and
ovaries (study group) and ten cases with total
hysterectomy were selected through a
random table among the referred menopause
patients for hormone replacement therapy.
Mean ages and menopause lengths of the
study and control groups were similar. Ten
cases and five controls had 15 days of
transdermal 100 µm/d estradiol (TE) (group
2), and similarly the other cases with five
controls had estradiol were measured at day
same period of time (group 1). Serum
CA125 and estradiol were measured at day 0
and by radio immunoassay (RIA). Statistics

Introduction
It is well known that menopause and hysterectomy
are important factors in reducing serum CA125 levels in
women. Previously, the endometrial CA125 secretion in
vitro has been shown in primary culture of human
endometrial stromal cells, its concentration in the
medium being significantly higher with cells obtained
during the proliferative and early secretory phases
compared with those obtained during the late secretory
phases (1). However, further studies are warranted to
understand the precise effects of estrogen and
progesterone on serum CA125 levels in menopausal
patients who have had or have not had hysterectomy.
Since exogenous estrogen restores the endometrial
activity in menopausal women, serum CA125 levels may
also show a coupled increase with the increased serum
estrogen levels. We report our preliminary findings from

were analysed by paired and unpaired
Student’s t test where appropriate.
Results: Serum mean CA 125 levels
increased in endometrium intact menopausal
women from day 0 to 15 of TE
administration in group 2 and 1, 70% and
6% respectively (p=0.03 and 0.05). Serum
estradiol accompanied this increase only in
group 2 significantly.
Conclusion: Endometrial CA125 secretion to
serum is dependent on the dose of exogenous
estrogen administered. Th subject population
used in this study is a good model to assess
the endometrial contribution of serum
CA125
with
exogenous
estrogen
administration by ruling out ovarian activity.
Key Words: Endometrial serum CA125,
serum estradiol, menopause.

a randomised, controlled, prospective study for the
assessment of estrogen administration on endogenous
serum CA125 levels in menopausal women with and
without intact uterus.
Materials ve Methods
Twenty menopausal women with intact uterus and
ovaries (study group) and ten cases with previous total
hysterectomy (control group) were included in the study.
Hysterectomy indications of the controls are outlined in
Table 1. Informed consent was obtained from all study
subjects and controls, randomly selected from clinic
patients by use of a random table. The mean ages of
subjects in the study and control groups were similar i.e.
53±1.9 (SD) and 51±2.7 years. The menopause lengths
in the study and control groups were also similar i.e.
61.0±18 and 52.6±26.5 months respectively.
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Group 1 consisted of ten cases and five controls,
randomly selected, who received 15 days of 50µgm/day
transdermal 17β–estradiol (TE). Group 2 consisted of a
further 10 cases and 5 controls, randomly selected, who
had 15 days of transdermal 100µgm/day 17β–estradiol
(Estraderm–Ciba) administration. Serum CA125 and
estradiol were measured at day 0 and 15 by radio
immunoassay (RIA). To prevent inter–assay variability,
serum of each case was frozen and counted once. CA125
and estradiol levels were measured using a solid phase
RIA with a sensitivity level of 0.5 U/ml (CIS–bio
international, France) and 8 pg/ml (DPC–Coat–a–count,
Los Angeles, Ca.) respectively. The inter–assay variability
was within a CV percentage of 3.2–4.2 for CA125 and
4.2–8.1 for estradiol. Because baseline CA125 levels in
menopausal women showed individual differences,
CA125 and serum estradiol levels before and after
exogenous estrogen administration were compared using
the paired t test.
Results
The results are presented in Table 2. In study groups
if CA125 levels significantly increased, serum estrogen
levels increased as well. In Group 2 100µgm/d TE
Table 1.

The diagnosis of the previous hysterectomised patients in
the control group.

Diagnosis

N

Benign myoma uteri
Submucous leiomyoma – necrosis
Endometrial polyp – necrosis
Abnormal vaginal bleeding with atrophic endometrium
Abnormal vaginal bleeding with focal hyperplasia

5
1
1
1
2

administration resulted in a 70% CA125 increase on day
15 (p=0.03) with an accompanying increase in serum
estradiol levels (p<0.03). In Group 1, 50µgm/d TE
administration resulted in a 6% increase in serum CA125
levels at the significance level of p=0.05 with an
insignificant concomitant inrease in estrogen levels.
Discussion
The major finding of this study is that endometrium
intact menopausal women respond to 15 days of 100
µgm/day TE administration with a significant increase
(70%) in the serum CA125 level. On the other hand, 15
days of 50 µgm/day TE results in a less significant
increase in the serum CA125 level (6%) in this sample
size (p=0.05). These findings are consistent with the
previous in vitro findings which show that stimulation of
endometrial cells causes increased CA125 secretion (2,
3).
A recent review has reported the menstrual
cycle–dependent expression of CA125 in normal tissues
of the female reproductive tract in relation to the actual
circulating CA125 levels, together with in vivo data
concerning the inductive effect of medroxyprogesterone
acetate on circulating CA125 in 24 post menopausal
women (4). The results of our study, where 100µgm/d
TE administration resulted in a 70% CA125 increase on
day 15 with an accompanying increase in serum estradiol
levels, supports the induction hypothesis above.
While CA125 may increase in non-reproductive
system related conditions such as mesothelioma,
tuberculosis, gastric carcinomas, breast cancer, mainly
reproductive system related conditions such as pregnancy,
leiomyoma, pelvic inflammatory disease, endometriosis,
endometrial–tubal or ovarian carcinoma increase
circulating CA125 levels (5). None of the cases in this
Table 2.

Day
CA125

Group 1
Group 2

S. Estradiol

Group 1
Group 2

(¶= 0.05, †p= 0.03, *p<0.03)
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0

15

Study
Control
Study
Control

17.2±2.5
17.9±5.8
11.6±1.7
10.5±1.8

18.2±2.6 ¶
17.1±5.1
19.7±4.1 †
14.3±3.7

Study
Control
Study
Control

26.7±10.7
25.0±4.5
16.3±3.6
27.7±11.6

86.0±8.7
40.2±6.5
140.8±32.8*
125.6±41.8*

Serum mean (±SEM)
CA125 and estradiol levels
in study and control group
before and after 15 days of
50–100
µgm/d
TE
administration in group 1
and 2 respectively.
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study had been diagnosed with any of these conditions
except menopause. All of our mean results among the
groups were lower than the tumour cut–off value (<35
U/ml) and were within 10–18 U/ml throughout the study.
Previously, hormone replacement therapy in menopause
has been shown to increase the baseline mean CA125
levels by 20% where the calculated cut–off value to
detect endometrial carcinoma has been reporteD to be 20
U/ml for menopausal individuals (6). Takami (6) and
Kurihara (7) found mean CA125 in normal menopausal
women to be 5.5 and 10.8 U/ml respectively and
advocated that each laboratory should establish its own
normal range.
In summary, the results of this study indicate that the
serum CA125 level is influenced by the serum blood
estrogen level and is dependent on the estrogen dose
administered. Thus, in menopause, estrogen replacement
therapy may increase the baseline CA125 in relation to
the dose of estrogen administered. However, this

therapeutic dose of estrogen increases CA125 around
20U/ml, which is far below the cut–off point previously
reported (6).
The subject population used in this study is a good
model to assess the endometrial contribution of serum
CA125 with exogenous estrogen administration by ruling
out ovarian activity. However, this study has certain
limitations regarding the conclusions to be drawn from
the limited sample size. Due to the preliminary nature of
the study, the current results reflect our findings without
any predetermined sample size and power calculations.
Thus, a larger study with a higher sample size may be
beneficial for the assessment of the effects caused by 50
µgm/day TE administration on the serum CA125.
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